Guideline on the pharmacokinetic and clinical …
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) 4/38 69 Executive summary
Download Guideline on the pharmacokinetic and clinical …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Guideline on the pharmacokinetic and clinical …
www.ema.europa.euThe primary purpose of this guideline is to define the studies necessary to investigate the efficacy , safety, biopharmaceutic and pharmacokinetic properties of modified release formulations following
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comRegistration of Medicines Biosimilars . MEDICINES CONTROL COUNCIL. BIOSIMILAR MEDICINES QUALITY, NON-CLINICAL AND CLINICAL REQUIREMENTS
New Zealand Data Sheet - Medsafe Home Page
www.medsafe.govt.nz2 LEVOTHYROXINE Levothyroxine Tablets 50 microgram and 100 microgram Page 2 of 10 where there is latent myocardial ischaemia), dosage must be reduced or withheld for a
DOXIUM 500 OM Pharma - Modern Medicine
www.meppo.comas high fever, oral cavity infections (tonsillitis), sore throat, anogenital inflammation and accompanying symptoms, that are often signs of an infection.
FENOFIBRATE 160 MG TABLETS PL 33217/0005 - …
www.mhra.gov.ukUKPAR Fenofibrate 160 mg Tablets PL 33217/0005 5 PHARMACEUTICAL ASSESSMENT ACTIVE SUBSTANCE INN: Fenofibrate Chemical Name: 1-methylethyl-2-[4-(4-chlorobenzoyl)phenoxy]-2-
DEVELOPMENT OF PAEDIATRIC MEDICINES: …
www.who.int- 5 - (1.1) have been derived mainly from physiological and pharmacokinetic differences from birth to adult: • preterm newborn infants; • term newborn infants (0–27 days);